Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 64 items for :

  • tyrosine kinase inhibitor x
Clear All
Kirsten E. Stewart Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed Close
,
Mark W.J. Strachan Metabolic Unit, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed Close
,
Devraj Srinivasan Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed Close
,
Morna MacNeill Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Search for other papers by Morna MacNeill in
Google Scholar
PubMed Close
,
Lucy Wall Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Lucy Wall in
Google Scholar
PubMed Close
, and
Iain J. Nixon Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Iain J. Nixon in
Google Scholar
PubMed Close

). What Does This Case Report Add? This case illustrates a patient with locally advanced DTC treated with tyrosine kinase inhibitor (TKI) therapy, which markedly reduced tumour volume and allowed subsequent successful surgical resection without

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000494880
Volume/Issue:
Volume 8: Issue 2
Free access
Satoshi Koyama Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Satoshi Koyama in
Google Scholar
PubMed Close
,
Naritomo Miyake Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Naritomo Miyake in
Google Scholar
PubMed Close
,
Kazunori Fujiwara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed Close
,
Tsuyoshi Morisaki Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed Close
,
Takahiro Fukuhara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed Close
,
Hiroya Kitano Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan

Search for other papers by Hiroya Kitano in
Google Scholar
PubMed Close
, and
Hiromi Takeuchi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed Close

strategies are required to improve the prognosis. Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1–3, FGFR1–4, RET, KIT, and PDGFRβ [ 6 - 8 ]. It was associated with a marked improvement in progression-free survival in patients with

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000485972
Volume/Issue:
Volume 7: Issue 3
Free access
Laura Ximena Kattah Martinez Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed Close
,
Lisseth Fernanda Marín Carrillo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed Close
, and
Leonardo Rojas Melo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed Close

What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000488316
Volume/Issue:
Volume 7: Issue 3
Free access
Markus Eszlinger Departments of Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed Close
,
Paul Stewardson Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Paul Stewardson in
Google Scholar
PubMed Close
,
John B McIntyre Precision Oncology Hub Laboratory, Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John B McIntyre in
Google Scholar
PubMed Close
,
Adrian Box Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Adrian Box in
Google Scholar
PubMed Close
,
Moosa Khalil Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Moosa Khalil in
Google Scholar
PubMed Close
,
Martin Hyrcza Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Martin Hyrcza in
Google Scholar
PubMed Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed Close
,
Dean Ruether Section of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Dean Ruether in
Google Scholar
PubMed Close
,
Jiahui Wu Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Jiahui Wu in
Google Scholar
PubMed Close
, and
Ralf Paschke Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

Introduction The neurotrophic tyrosine kinase receptor (NTRK) inhibitors, larotrectinib and entrectinib, were approved by the United States Food & Drug Administration (FDA) for the treatment of NTRK fusion-positive solid tumors that are

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-21-0061
Volume/Issue:
Volume 11: Issue 1
Open access
Luisa Paschke Department of Endocrinology and Nephrology, Division of Endocrinology, University Clinic Leipzig, Leipzig, Germany
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Luisa Paschke in
Google Scholar
PubMed Close
,
Thomas Lincke Department of Radiology, Division of Nuclear Medicine, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Thomas Lincke in
Google Scholar
PubMed Close
,
Katja Sibylle Mühlberg Department of Angiology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed Close
,
Wolfram J. Jabs Department of Nephrology, Vivantes Clinics, Berlin, Germany

Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed Close
,
Tom H. Lindner Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Tom H. Lindner in
Google Scholar
PubMed Close
, and
Ralf Paschke Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

treatment with lenvatinib and no concerning co-medications were reported. What Does This Case Report Add? We report two severe AEs of anti-VEGF tyrosine kinase inhibitor treatment which were not reported in the phase III trials. Our case

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000491387
Volume/Issue:
Volume 7: Issue 6
Free access
Francisco Sousa Santos Endocrinology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed Close
,
Rita Joana Santos Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Rita Joana Santos in
Google Scholar
PubMed Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed Close

a part in the pathogenesis of thyroid cancer and these represent potential treatment targets [ 6 ]. As such, several multitargeted tyrosine kinase inhibitors (TKIs) have been investigated for the treatment of RAI-refractory thyroid cancer with the

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000501680
Volume/Issue:
Volume 8: Issue 5
Free access
Simone De Leo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Carla Colombo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Marta Di Stefano Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Marta Di Stefano in
Google Scholar
PubMed Close
,
Antonella Dubini Division of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Antonella Dubini in
Google Scholar
PubMed Close
,
Silvia Cozzi Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Silvia Cozzi in
Google Scholar
PubMed Close
,
Luca Persani Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed Close
, and
Laura Fugazzola Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

biological characteristics of this tumor, which has a relatively low growth rate and is poorly symptomatic. Nevertheless, patients experience a relevant weight decrease when treatment with a tyrosine kinase inhibitor (TKI) is started, such as lenvatinib

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000504048
Volume/Issue:
Volume 9: Issue 1
Free access
Sita Virakul Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam

Search for other papers by Sita Virakul in
Google Scholar
PubMed Close
,
Leendert van Steensel Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Leendert van Steensel in
Google Scholar
PubMed Close
,
Virgil A.S.H. Dalm Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Virgil A.S.H. Dalm in
Google Scholar
PubMed Close
,
Dion Paridaens Rotterdam Eye Hospital, Rotterdam, The Netherlands
Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland

Search for other papers by Dion Paridaens in
Google Scholar
PubMed Close
,
P. Martin van Hagen Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam
Rotterdam Eye Hospital, Rotterdam, The Netherlands

Search for other papers by P. Martin van Hagen in
Google Scholar
PubMed Close
, and
Willem A. Dik Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Willem A. Dik in
Google Scholar
PubMed Close

fibroblast functions In recent years numerous novel, targeted therapies have been introduced in clinical practice, like the biologicals and tyrosine kinase inhibitors (TKIs). Therapeutic strategies that target specific cytokines, growth factors or

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000367968
Volume/Issue:
Volume 3: Issue 4
Free access
Roberto Fiore Division of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Hôtel des Patients, Lausanne, Switzerland

Search for other papers by Roberto Fiore in
Google Scholar
PubMed Close
,
Stefano La Rosa Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Stefano La Rosa in
Google Scholar
PubMed Close
,
Silvia Uccella Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Silvia Uccella in
Google Scholar
PubMed Close
,
Deborah Marchiori Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Deborah Marchiori in
Google Scholar
PubMed Close
, and
Peter A Kopp Division of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Hôtel des Patients, Lausanne, Switzerland

Search for other papers by Peter A Kopp in
Google Scholar
PubMed Close

hypothyroidism was first induced by systemic therapy with checkpoint inhibitors, and then further complicated by consumptive hypothyroidism. In this context, it is worthwhile mentioning that D3 activity can be increased by therapy with tyrosine kinase inhibitors

Article Type:
Case Report
Collections:
Hypothyroidism
DOI:
https://doi.org/10.1530/ETJ-22-0006
Volume/Issue:
Volume 11: Issue 5
Open access
Zoe A. Efstathiadou Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece

Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed Close
,
Charalambos Tsentidis Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece

Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed Close
,
Alexandra Bargiota Department of Endocrinology, University of Thessaly, Larisa, Greece

Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed Close
,
Vasiliki Daraki Department of Endocrinology, University Hospital of Crete, Heraklion, Greece

Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed Close
,
Kalliopi Kotsa Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece

Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed Close
,
Georgia Ntali Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece

Search for other papers by Georgia Ntali in
Google Scholar
PubMed Close
,
Labrini Papanastasiou Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece

Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed Close
,
Stelios Tigas Department of Endocrinology, University of Ioannina, Ioannina, Greece

Search for other papers by Stelios Tigas in
Google Scholar
PubMed Close
,
Konstantinos Toulis Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece

Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed Close
,
Kalliopi Pazaitou-Panayiotou Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece

Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed Close
, and
Maria Alevizaki Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Alevizaki in
Google Scholar
PubMed Close

well as in the associated side effects [ 3 , 7 ]. Tyrosine kinase inhibitors (TKIs) are small molecules that target intracellular signaling pathways at different sites and, to date, they are the mainstay treatment for advanced MTC. Cabozantinib and

Article Type:
Meta Analysis
DOI:
https://doi.org/10.1159/000509457
Volume/Issue:
Volume 10: Issue 2
Free access